Nutriband Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nutriband Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative transdermal drug delivery systems, primarily focusing on abuse-deterrent pharmaceutical products. Its core product portfolio includes AVERSA™, an abuse-deterrent transdermal technology applied to opioid patches such as fentanyl and buprenorphine, designed to reduce misuse while maintaining therapeutic efficacy. The company also develops transdermal solutions for peptides, proteins, biologics, and other drugs traditionally administered through injections, aiming to improve patient compliance, safety, and outcomes. Nutriband operates through its clinical subsidiary 4P Therapeutics, which manages pharmaceutical product development from preclinical to early clinical stages. Founded in 2016 and headquartered in Orlando, Florida, Nutriband targets the global pharmaceutical and medical device industries, focusing on addressing the opioid epidemic and providing safer alternatives for pain management. Its lead product, AVERSA Fentanyl, benefits from a commercial development and clinical supply agreement with Kindeva Drug Delivery, a global contract development and manufacturing organization. Nutriband’s product development strategy leverages FDA regulatory pathways, aiming for streamlined approval processes such as a New Drug Application (NDA) filing supported by a single phase 1 Human Abuse Potential study. Recent major developments include Nutriband's successful meeting with the U.S. FDA regarding AVERSA Fentanyl, an $8.4 million private placement completed in 2024 to fund clinical development, and the exercise of warrants generating over $5 million in gross proceeds to support these initiatives. The company is advancing toward an NDA filing targeted for early 2025, with projections of peak U.S. sales ranging from $80 million to $200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine. Nutriband also holds patents across 46 countries for its abuse-deterrent transdermal technology, reflecting its commitment to innovative drug delivery solutions. Nutriband’s strategic expansions include acquisitions that enhanced its intellectual property and manufacturing capabilities, partnering with specialized contract manufacturers, and operational advances under returning leadership, including the reinstatement of co-founder Gareth Sheridan as CEO. The company's ongoing clinical and regulatory activities, along with its strong patent portfolio and manufacturing partnerships, position it as a leader in transdermal pharmaceutical innovation addressing significant unmet medical needs globally.
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Reviewing electroCore (NASDAQ:ECOR) & Nutriband (NASDAQ:NTRB)
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
Nutriband CEO Publishes Letter to Shareholders
What's Going On With Nutriband Stock Monday?
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
Head to Head Review: Nutriband (NASDAQ:NTRB) vs. Quoin Pharmaceuticals (NASDAQ:QNRX)
Nutriband (NTRB) Expected to Announce Quarterly Earnings on Tuesday
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference
Nutriband Inc. to Present at the MicroCap Rodeo Conference
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl